NasdaqGS:ONCBiotechs
How Chemotherapy-Free Phase 3 MCL Success At BeOne Medicines (ONC) Has Changed Its Investment Story
BeOne Medicines Ltd. recently reported positive topline results from its Phase 3 MANGROVE trial, where BRUKINSA (zanubrutinib) plus rituximab significantly improved progression-free survival versus bendamustine plus rituximab in previously untreated mantle cell lymphoma.
This is the first global Phase 3 study to show a chemotherapy-free, rituximab maintenance-free regimen can match or exceed standard chemoimmunotherapy, potentially sparing patients around two years of infusion treatment...